EZH2 was identified to confer resistance of ESCC cells to PI3Kα inhibitors, which was further confirmed by the negative correlation of CYH33 activity and EZH2 expression in multiple ECSS cell lines and patient‐derived cells. This evidence concerns the gene EZH2 and esophageal squamous cell carcinoma.